Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 11, 2008, Pages 1279-1285

  Stinchcombe, Thomas E ^a,c   Lee, Carrie B ^a   Moore, Dominic T ^b   Rivera, M Patricia ^c   Halle, Jan ^c   Limentani, Steven ^d   Rosenman, Julian G ^c   Socinski, Mark A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d CAROLINAS MEDICAL CENTER   (United States)

Author keywords

Carboplatin; Combined modality therapy; Conformal thoracic therapy; High dose; Locally advanced non small cell lung cancer; Paclitaxel

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; TUMOR GROWTH; WEIGHT REDUCTION; FEASIBILITY STUDY; LUNG TUMOR; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; REMISSION; SURVIVAL RATE; TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; RADIOTHERAPY, CONFORMAL; REMISSION INDUCTION; SURVIVAL RATE; TIME FACTORS;

EID: 58949098154     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818b1971     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003. Chest 2005;128:452-462.
3. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
4. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: update 2003. J Clin Oncol 2004;22:330-353.
5. Furuse K, for the West Japan Lung Cancer Group. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-2699.
6. Curran WJ, Scott C, Langer C. Phase III comparison of sequential vs concurrent chemoradiation for PTS with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol 2000;19:484a (abstract 1891).
7. Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 1992;326:524-530.
8. Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group. Cancer 1980;45:2744-2753.
9. Le Chevalier T, Arrigada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non-resectable non-small cell lung cancer: first analysis of randomized trial in 353 patients. J Natl Cancer Inst 1991;83:417-423.
10. Socinski MA, Rosenman JG, Schell MJ, et al. Induction carboplatin/ paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small cell lung carcinoma: a modified Phase I trial. Cancer 2000; 89:534-542.
11. Socinski MA, Rosenman JG, Halle J, et al. Dose-escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/ paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified phase I/II trial. Cancer 2001;92:1213-1223.
12. Beahrs O, Henson D, Hutter R, Myers M, (Eds.) Manual for staging of cancer, 3rd Ed. Philadelphia: Lippincott, 1988.
13. Detterbeck FC, Socinski MA. IIB or not IIB: the current question in staging non-small cell lung cancer. Chest 1997;112:229-234.
14. Calvert A, Newell D, Gumbrell L, O'Reilly S, Burnell M, Boxall F. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-1756.
15. Rosenman JG, Halle JS, Socinski MA, et al. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 2002;54:348-356.
16. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
18. Stinchcombe TE, Walters R, Khandani AH, Socinski MA. Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer. J Clin Oncol 2007;25:1621-1623.
19. Vokes EE, Herndon JE II, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007;25:1698- 1704.
20. Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004-2010.
21. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-2456.
22. Hanna NH, Neubauer M, Ansari R, et al. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent Chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): HOG LUN 01-24/USO-023., 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 2518S:abstract 7512.
23. Morgensztern D, Goodgame B, Baggstrom MQ, Gao F, Govindan R. The effect of FDG-PET on the stage distribution of non-small cell lung cancer. J Thorac Oncol 2008;3:135-139.
24. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293.
25. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005;23:2955-2961.
26. Mamon HJ, Yeap BY, Janne PA, et al. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol 2005;23:1530-1537.
27. Pugh TJ, Gaspar LE. Prophylactic cranial irradiation for patients with lung cancer. Clin Lung Cancer 2007;8:365-368.
28. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta-analysis of randomized clinical trials comparing Cisplatin to Car-boplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 2004;22:3852-3859.
29. Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst 2007;99:847-857.
30. Kim M, Kim S, Choi E, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus concurrent chemotherapy (CCRT) alone for unresectable non-small cell lung cancer: randomized phase III trial. J Thorac Oncol 2007;2:S308.
31. Bradley JD, Graham M, Suzanne S, et al. Phase I Results of RTOG L-0117; a Phase I/II Dose Intensification Study Using 3DCRT and Concurrent Chemotherapy for Patients with Inoperable NSCLC. J Clin Oncol 2005 ASCO Annual Meeting Proceedings 2005;23(16S, Part I of II June 1 Supplement):abstract 7063, 636s.
32. Schild SE, McGinnis WL, Graham D, et al. Results of a Phase I trial of concurrent chemotherapy and escalating doses of radiation for unresect-able non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006;65: 1106-1111.
33. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008;26: 2457-2463.
34. Vokes EE, Herndon JE II, Crawford J, et al. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 2002;20:4191-4198.
35. RTOG 0617. Available at www.clinicaltrials.gov-assessed. Accessed May 21, 2008.